S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT01498289, this PHASE2 trial focuses on Adenocarcinoma of the Gastroesophageal Junction and Esophageal Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 15 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .